J.P. Morgan Initiates ProKidney(PROK.US) With Hold Rating
Maintaining Hold on ProKidney: Balancing Potential Against Need for Further Efficacy Data
Express News | ProKidney Corp : JP Morgan Initiates Coverage With Neutral Rating
Insiders Who Purchased US$54.7m Of ProKidney Stock May Not Have Expected 24% Tumble
ProKidney Executive Sells $41,030 in Company Stock
ProKidney Initiated at Buy by Guggenheim
Guggenheim Initiates Coverage On ProKidney With Buy Rating, Announces Price Target of $6
Guggenheim Initiates ProKidney(PROK.US) With Buy Rating, Announces Target Price $6
Guggenheim analyst Vamil Divan initiates coverage on $ProKidney(PROK.US)$ with a buy rating, and sets the target price at $6.According to TipRanks data, the analyst has a success rate of 53.5% and a
Buy Rating on ProKidney: Promising Prospects in Chronic Kidney Disease Treatment
ProKidney Drops Phase III CKD Study to Focus on US Market and Save up to $175m
BofA Securities Maintains ProKidney(PROK.US) With Hold Rating, Maintains Target Price $3
BofA Securities analyst Jason Gerberry maintains $ProKidney(PROK.US)$ with a hold rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 43.7% and
ProKidney Is Maintained at Neutral by B of A Securities
B of A Securities Maintains Neutral on ProKidney, Lowers Price Target to $3
ProKidney Analyst Ratings
BofA Securities Maintains ProKidney(PROK.US) With Hold Rating, Cuts Target Price to $3
BofA Securities analyst Jason Gerberry maintains $ProKidney(PROK.US)$ with a hold rating, and adjusts the target price from $4 to $3.According to TipRanks data, the analyst has a success rate of 43.7%
Morgan Stanley Maintains ProKidney(PROK.US) With Hold Rating, Maintains Target Price $3
Morgan Stanley analyst Judah Frommer maintains $ProKidney(PROK.US)$ with a hold rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 47.7% and a
Maintaining Hold on ProKidney Amid Strategic Shifts and Regulatory Uncertainties
ProKidney's Hold Rating Maintained Amid Financing and Clinical Uncertainties
BTIG Maintains ProKidney(PROK.US) With Buy Rating, Maintains Target Price $5
BTIG analyst Justin Zelin maintains $ProKidney(PROK.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 41.8% and a total
ProKidney: Investor Update and Phase 3 Program Progress